{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:08:13Z","timestamp":1791497293466,"version":"4.3.4"},"reference-count":142,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Regulatory T cells (Tregs) are responsible for maintaining immune homeostasis by controlling immune responses. They can be characterized by concomitant expression of FoxP3, CD25 and inhibitory receptors such as PD-1 and CTLA-4. Tregs are key players in preventing autoimmunity and are dysregulated in cancer, where they facilitate tumor immune escape. B-cell lymphoid malignancies are a group of diseases with heterogenous molecular characteristics and clinical course. Treg levels are increased in patients with B-cell lymphoid malignancies and correlate with clinical outcomes. In this review, we discuss studies investigating Treg immunobiology in B-cell lymphoid malignancies, focusing on clinical correlations, mechanisms of accumulation, phenotype, and function. Overarching trends suggest that Tregs can be induced directly by tumor cells and recruited to the tumor microenvironment where they suppress antitumor immunity to facilitate disease progression. Further, we highlight studies showing that Tregs can be modulated by novel therapeutic agents such as immune checkpoint blockade and targeted therapies. Treg disruption by novel therapeutics may beneficially restore immune competence but has been associated with occurrence of adverse events. Strategies to achieve balance between these two outcomes will be paramount in the future to improve therapeutic efficacy and safety.<\/jats:p>","DOI":"10.3389\/fimmu.2022.943354","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:36:03Z","timestamp":1659314163000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies"],"prefix":"10.3389","volume":"13","author":[{"given":"Kamira","family":"Maharaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angimar","family":"Uriepero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Sahakian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357","article-title":"US Lymphoid malignancy statistics by world health organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large b-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter Transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL study group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf","year":"2021","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.46883\/2022.25920946","article-title":"Follicular lymphoma: a focus on current and emerging therapies","volume":"36","author":"Cahill","year":"2022","journal-title":"Oncol (Williston Park)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d'Etudes des lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.21037\/aol.2019.09.01","article-title":"New drugs for the management of relapsed or refractory diffuse large B-cell lymphoma","volume":"3","author":"Sarkozy","year":"2019","journal-title":"Ann Lymphoma"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S265284","article-title":"The role of BTK inhibition in the treatment of chronic lymphocytic leukemia: A clinical view","volume":"13","author":"Tambaro","year":"2021","journal-title":"J Exp Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000847","article-title":"The immune landscape and response to immune checkpoint blockade therapy in lymphoma","volume":"135","author":"Kline","year":"2020","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-021-01134-x","article-title":"Targeting the tumor microenvironment in b-cell lymphoma: challenges and opportunities","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457531","article-title":"T Cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1678154","article-title":"STAT3, tumor microenvironment, and microvessel density in diffuse large b cell lymphomas","volume":"61","author":"Tamma","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35017","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/cancers13040641","article-title":"Follicular lymphoma microenvironment: An intricate network ready for therapeutic intervention","volume":"13","author":"Dobano-Lopez","year":"2021","journal-title":"Cancers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.03.003","article-title":"Follicular helper T cells: lineage and location","volume":"30","author":"Fazilleau","year":"2009","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243626","article-title":"Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large b-cell lymphoma","volume":"106","author":"Autio","year":"2021","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006809","article-title":"Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia","volume":"1","author":"Maharaj","year":"2017","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI57175","article-title":"Control of inflammation by integration of environmental cues by regulatory T cells","volume":"123","author":"Chaudhry","year":"2013","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00190","article-title":"Natural and induced T regulatory cells in cancer","volume":"4","author":"Adeegbe","year":"2013","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ni909","article-title":"An essential role for scurfin in CD4+CD25+ T regulatory cells","volume":"4","author":"Khattri","year":"2003","journal-title":"Nat Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1158\/1557-3125.HIPPO19-B11","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00051","article-title":"Molecular mechanisms of treg-mediated T cell suppression","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/bs.acr.2019.05.001","article-title":"Expression of costimulatory and inhibitory receptors in FoxP3(+) regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches","volume":"144","author":"Toker","year":"2019","journal-title":"Adv Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1756-8722-4-50","article-title":"The four types of tregs in malignant lymphomas","volume":"4","author":"Wang","year":"2011","journal-title":"J Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2487","article-title":"A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1\u2013positive, regulatory, cytotoxic, and helper T cells and macrophages","volume":"16","author":"Wahlin","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.11702","article-title":"Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large b-cell lymphoma, follicular lymphoma and classical hodgkin's lymphoma","volume":"93","author":"Tzankov","year":"2008","journal-title":"Haematologica"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235598","article-title":"The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation","volume":"115","author":"Farinha","year":"2010","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.291","article-title":"Automated prognostic pattern detection shows favourable diffuse pattern of FOXP3(+) tregs in follicular lymphoma","volume":"113","author":"Nelson","year":"2015","journal-title":"Br J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701824536","article-title":"Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large b-cell lymphoma at diagnosis","volume":"49","author":"Lee","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-014-1615-5","article-title":"Expression of PD-1 (CD279) and FoxP3 in diffuse large b-cell lymphoma","volume":"465","author":"Ahearne","year":"2014","journal-title":"Virchows Arch"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.879713","article-title":"An increase of M2 macrophages predicts poor prognosis in patients with diffuse large b-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone","volume":"55","author":"Nam","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/10428194.2020.1817438","article-title":"Higher infiltration of intratumoral CD25+ FOXP3+ lymphocytes correlates with a favorable prognosis in patients with diffuse large b-cell lymphoma","volume":"62","author":"Chang","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02591-y","article-title":"Aberrant peripheral blood CD4(+) CD25(+) FOXP3(+) regulatory T cells\/T helper-17 number is associated with the outcome of patients with lymphoma","volume":"69","author":"Dehghani","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03398-1","article-title":"Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis","volume":"146","author":"Peng","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151100","article-title":"T Cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma","year":"2017","journal-title":"Haematologica"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.08.010","article-title":"Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease","volume":"35","author":"D'Arena","year":"2011","journal-title":"Leuk Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.728287","article-title":"Regulatory T-cells in b-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias","volume":"54","author":"Lad","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.leukres.2017.07.004","article-title":"Quantitative and qualitative analysis of regulatory T cells in b cell chronic lymphocytic leukemia","volume":"60","author":"Mpakou","year":"2017","journal-title":"Leukemia Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23170","article-title":"A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with rai stage 0 chronic lymphocytic leukemia","volume":"87","author":"D'Arena","year":"2012","journal-title":"Am J Hematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25752","article-title":"Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia","volume":"117","author":"Weiss","year":"2011","journal-title":"Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.986479","article-title":"Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias","volume":"56","author":"Lad","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-105395","article-title":"Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma","volume":"111","author":"Mittal","year":"2008","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-082578","article-title":"CD70+ non-Hodgkin lymphoma b cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells","volume":"110","author":"Yang","year":"2007","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010527","article-title":"SOX11, CD70, and treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma","volume":"138","author":"Balsas","year":"2021","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.804917","article-title":"Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration","volume":"55","author":"Liu","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0589","article-title":"Follicular b lymphomas generate regulatory T cells via the ICOS\/ICOSL pathway and are susceptible to treatment by anti-ICOS\/ICOSL therapy","volume":"76","author":"Le","year":"2016","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.165","article-title":"Chronic lymphocytic leukemia and regulatory b cells share IL-10 competence and immunosuppressive function","volume":"27","author":"DiLillo","year":"2013","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2006.02377.x","article-title":"Role of BAFF and APRIL in human b-cell chronic lymphocytic leukaemia","volume":"118","author":"Haiat","year":"2006","journal-title":"Immunology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.174","article-title":"The BAFF receptor TACI controls IL-10 production by regulatory b cells and CLL b cells","volume":"30","author":"Saulep-Easton","year":"2016","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001091","article-title":"Targeting CD38 is lethal to breg-like chronic lymphocytic leukemia cells and tregs, but restores CD8+ T-cell responses","volume":"4","author":"Manna","year":"2020","journal-title":"Blood Adv"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201363","article-title":"Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment","volume":"190","author":"Rawal","year":"2013","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155347","article-title":"Follicular lymphoma tregs have a distinct transcription profile impacting their migration and retention in the malignant lymph node","volume":"11","author":"Nedelkovska","year":"2016","journal-title":"PloS One"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-546416","article-title":"CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00333","article-title":"Organ-specific and memory treg cells: specificity, development, function, and maintenance","volume":"5","author":"Gratz","year":"2014","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1822","article-title":"Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in b-cell non-hodgkin's lymphoma","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3376","article-title":"Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in b-cell non-Hodgkin lymphoma","volume":"107","author":"Yang","year":"2006","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12943-022-01516-w","article-title":"BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion","volume":"21","author":"Liu","year":"2022","journal-title":"Mol Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3390\/cancers14051276","article-title":"Targeted agents in the treatment of indolent b-cell non-hodgkin lymphomas","volume":"14","author":"Minson","year":"2022","journal-title":"Cancers"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0901166106","article-title":"E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction","volume":"106","author":"Gorgun","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.781364","article-title":"A specific CD44lo CD25lo subpopulation of regulatory T cells inhibits anti-leukemic immune response and promotes the progression in a mouse model of chronic lymphocytic leukemia","volume":"13","author":"Goral","year":"2022","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3892\/or_00000059","article-title":"Characterization of regulatory T cells in patients with b-cell chronic lymphocytic leukemia","volume":"20","author":"Giannopoulos","year":"2008","journal-title":"Oncol Rep"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0419","article-title":"Regulatory T cells in an endogenous mouse lymphoma recognize specific antigen peptides and contribute to immune escape","volume":"7","author":"Ahmetlic","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.3.1469","article-title":"Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by fas-mediated apoptosis","volume":"182","author":"Strauss","year":"2009","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1365-2567.2011.03439.x","article-title":"Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with b-cell malignancy express cytolytic markers and kill autologous leukaemic b cells in vitro","volume":"133","author":"Lindqvist","year":"2011","journal-title":"Immunology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12967-018-1545-0","article-title":"Immunosuppressive treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients","volume":"16","author":"De Matteis","year":"2018","journal-title":"J Transl Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.cell.2017.05.005","article-title":"Interferon-gamma drives treg fragility to promote anti-tumor immunity","volume":"169","author":"Overacre-Delgoffe","year":"2017","journal-title":"Cell"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-183251","article-title":"IL-17-producing human peripheral regulatory T cells retain suppressive function","volume":"113","author":"Beriou","year":"2009","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/vaccines4030028","article-title":"Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting","volume":"4","author":"Chaudhary","year":"2016","journal-title":"Vaccines"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.039446","article-title":"Inflammation, the microenvironment and chronic lymphocytic leukemia","volume":"96","author":"Caligaris-Cappio","year":"2011","journal-title":"Haematologica"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.164","article-title":"Phenotypic complexity of T regulatory subsets in patients with b-chronic lymphocytic leukemia","volume":"25","author":"Biancotto","year":"2012","journal-title":"Mod Pathol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-Expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00727","article-title":"What else can CD39 tell us","volume":"8","author":"Zhao","year":"2017","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.708874","article-title":"CD8(+) regulatory T cell - a mystery to be revealed","volume":"12","author":"Mishra","year":"2021","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2012.756110","article-title":"Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression","volume":"31","author":"Jadidi-Niaragh","year":"2013","journal-title":"Cancer Invest"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0296-3","article-title":"Modulation of regulatory T cell function and stability by co-inhibitory receptors","volume":"20","author":"Lucca","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016000885","article-title":"Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large b-cell lymphoma, not otherwise specified","volume":"1","author":"Nakayama","year":"2017","journal-title":"Blood Adv"},{"key":"B86","doi-asserted-by":"publisher","first-page":"107662","DOI":"10.1016\/j.intimp.2021.107662","article-title":"High levels of Tim-3(+)Foxp3(+)Treg cells in the tumor microenvironment is a prognostic indicator of poor survival of diffuse large b cell lymphoma patients","volume":"96","author":"Zhong","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0277-x","article-title":"The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity","volume":"30","author":"Schnell","year":"2020","journal-title":"Cell Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2337","article-title":"T Cells expressing checkpoint receptor TIGIT are enriched in follicular lymphoma tumors and characterized by reversible suppression of T-cell receptor signaling","volume":"24","author":"Josefsson","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001390","article-title":"LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large b-cell lymphoma","volume":"4","author":"Keane","year":"2020","journal-title":"Blood Adv"},{"key":"B90","doi-asserted-by":"publisher","first-page":"101170","DOI":"10.1016\/j.tranon.2021.101170","article-title":"Immune checkpoint blockade impairs immunosuppressive mechanisms of regulatory T cells in b-cell lymphoma","volume":"14","author":"Bauer","year":"2021","journal-title":"Transl Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792267","article-title":"Dual PD1\/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia","volume":"131","author":"Wierz","year":"2018","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26659","article-title":"Co-Inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models","volume":"10","author":"Greenberg","year":"2019","journal-title":"Oncotarget"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103768","article-title":"IL-2 receptor signaling is essential for the development of Klrg1+ terminally differentiated T regulatory cells","volume":"189","author":"Cheng","year":"2012","journal-title":"J Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402339","article-title":"CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia","volume":"16","author":"Durig","year":"2002","journal-title":"Leukemia"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017359","article-title":"The PI3K p110delta regulates expression of CD38 on regulatory T cells","volume":"6","author":"Patton","year":"2011","journal-title":"PloS One"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01536","article-title":"Unexpected help: Follicular regulatory T cells in the germinal center","volume":"9","author":"Xie","year":"2018","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.05.025","article-title":"The prevalence and function of CD4(+)CXCR5(+)Foxp3(+) follicular regulatory T cells in diffuse large b cell lymphoma","volume":"61","author":"Cha","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2020.05.008","article-title":"T Follicular helper cell-mediated IL-21 production suppresses FOXP3 expression of T follicular regulatory-like cells in diffuse large b cell lymphoma patients","volume":"81","author":"Ma","year":"2020","journal-title":"Hum Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.991731","article-title":"Nurse like cells: chronic lymphocytic leukemia associated macrophages","volume":"56","author":"Boissard","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.001","article-title":"The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases","volume":"49","author":"Roncarolo","year":"2018","journal-title":"Immunity"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01136-1","article-title":"EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4(+) T cells in chronic lymphocytic leukemia","volume":"35","author":"Roessner","year":"2021","journal-title":"Leukemia"},{"key":"B102","doi-asserted-by":"publisher","first-page":"8660","DOI":"10.3390\/cancers14040860","article-title":"Regulation of b-cell receptor signaling and its therapeutic relevance in aggressive b-cell lymphomas","volume":"14","author":"Profitos-Peleja","year":"2022","journal-title":"Cancers"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.268037","article-title":"Targeting the tumor microenvironment in chronic lymphocytic leukemia","volume":"106","author":"Svanberg","year":"2021","journal-title":"Haematologica"},{"key":"B104","doi-asserted-by":"publisher","first-page":"9513701","DOI":"10.1155\/2019\/9513701","article-title":"Immune checkpoint inhibition in classical Hodgkin lymphoma: From early achievements towards new perspectives","volume":"2019","author":"De Goycoechea","year":"2019","journal-title":"J Oncol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1002\/cncr.25983","article-title":"Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia","volume":"117","author":"Lee","year":"2011","journal-title":"Cancer"},{"key":"B106","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00262-016-1922-6","article-title":"Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints","volume":"66","author":"Winqvist","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003774","article-title":"Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma","volume":"5","author":"Menard","year":"2021","journal-title":"Blood Adv"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"key":"B109","doi-asserted-by":"publisher","first-page":"106432","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leuk Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16148","article-title":"Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number","volume":"8","author":"Podhorecka","year":"2017","journal-title":"Oncotarget"},{"key":"B111","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/hon.2667","article-title":"The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"37","author":"Zou","year":"2019","journal-title":"Hematol Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Advances"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701703","article-title":"The PI3K p110delta isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function","volume":"202","author":"Chellappa","year":"2019","journal-title":"J Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18053","article-title":"Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia","volume":"197","author":"Gadi","year":"2022","journal-title":"Br J Haematol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0438","article-title":"A phase I study of the combination of rituximab and ipilimumab in patients with Relapsed\/Refractory b-cell lymphoma","volume":"25","author":"Tuscano","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"8572","DOI":"10.3390\/ijms22168572","article-title":"Immunomodulatory drugs for the treatment of B cell malignancies","volume":"22","author":"Ioannou","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B117","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/08830185.2012.670334","article-title":"Tec family kinases in inflammation and disease","volume":"31","author":"Horwood","year":"2012","journal-title":"Int Rev Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2012.664798","article-title":"The role of tec family kinases in the regulation of T-helper-cell differentiation","volume":"31","author":"Boucheron","year":"2012","journal-title":"Int Rev Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131459","article-title":"Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells","volume":"211","author":"Gomez-Rodriguez","year":"2014","journal-title":"J Exp Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.668162","article-title":"Acalabrutinib: A selective bruton tyrosine kinase inhibitor for the treatment of b-cell malignancies","volume":"11","author":"Abbas","year":"2021","journal-title":"Front Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.011","article-title":"PI3K signaling pathway in normal b cells and indolent b-cell malignancies","volume":"43","author":"Pongas","year":"2016","journal-title":"Semin Oncol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.3390\/cancers13215535","article-title":"PI3K\u03b4 inhibitors as immunomodulatory agents for the treatment of lymphoma patients","volume":"13","author":"Tarantelli","year":"2021","journal-title":"Cancers"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00245","article-title":"The role of the PI3K signaling pathway in CD4(+) T cell differentiation and function","volume":"3","author":"Han","year":"2012","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.608625","article-title":"The PI3K partial differential-selective inhibitor idelalisib induces T- and NK-cell dysfunction independently of b-cell malignancy-associated immunosuppression","volume":"12","author":"Rohrbacher","year":"2021","journal-title":"Front Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99386","article-title":"PI3K p110delta inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression","volume":"129","author":"Dong","year":"2019","journal-title":"J Clin Invest"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001800","article-title":"The dual PI3Kdelta\/CK1epsilon inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells","volume":"4","author":"Maharaj","year":"2020","journal-title":"Blood Adv"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0318-3","article-title":"PI3Kdelta inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia","volume":"33","author":"Hanna","year":"2019","journal-title":"Leukemia"},{"key":"B129","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01441-9","article-title":"A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia","volume":"36","author":"Gadi","year":"2022","journal-title":"Leukemia"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S201024","article-title":"Copanlisib in the treatment of relapsed follicular lymphoma: Utility and experience from the clinic","volume":"13","author":"Chauhan","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3390\/cancers14061571","article-title":"PI3K inhibitors for the treatment of chronic lymphocytic leukemia: Current status and future perspectives","volume":"14","author":"Hus","year":"2022","journal-title":"Cancers"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001584","article-title":"PI3Kdelta inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax","volume":"4","author":"Serrat","year":"2020","journal-title":"Blood Adv"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.21037\/atm-20-6833","article-title":"Immune checkpoint inhibitors in lymphoma: challenges and opportunities","volume":"9","author":"Hatic","year":"2021","journal-title":"Ann Transl Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/imcb.1003","article-title":"Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells","volume":"96","author":"Sasidharan Nair","year":"2018","journal-title":"Immunol Cell Biol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory b-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0939-1","article-title":"A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed\/refractory lymphoid malignancies","volume":"35","author":"Armand","year":"2021","journal-title":"Leukemia"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory T cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.833667","article-title":"Functional diversities of regulatory T cells in the context of cancer immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.648663","article-title":"The role of PI3K inhibition in the treatment of breast cancer, alone or combined with immune checkpoint inhibitors","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/nature13444","article-title":"Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer","volume":"510","author":"Ali","year":"2014","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.943354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:36:06Z","timestamp":1659314166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.943354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":142,"alternative-id":["10.3389\/fimmu.2022.943354"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.943354","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"article-number":"943354"}}